Price Alert

Celcuity Inc. (CELC)

NASDAQ: CELC · Real-Time Price · USD

51.55

-0.24 (-0.46%)

At close: Aug 18, 2025, 3:59 PM

50.84

-1.38%

After-hours: Aug 18, 2025, 07:47 PM EDT

-0.46% (1D)

Bid	50.2
Market Cap	2.12B
Revenue (ttm)	n/a
Net Income (ttm)	-127.16M
EPS (ttm)	-3.47
PE Ratio (ttm)	-14.86
Forward PE	-13.29
Analyst	Buy

Ask	51.6
Volume	662,254
Avg. Volume (20D)	1,181,056.7
Open	52.16
Previous Close	51.79
Day's Range	50.00 - 53.05
52-Week Range	7.58 - 53.85
Beta	0.68

About CELC

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol CELC

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for CELC stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

3 weeks ago

+4.65%

Celcuity shares are trading higher after HC Wainwr... Unlock content with Pro Subscription

3 weeks ago

+167.18%

Celcuity shares are trading higher after the company released topline results from its PIK3CA wild-type cohort of its Phase 3 VIKTORIA-1 trial.

News

4 days ago · seekingalpha.com

Celcuity Inc. (CELC) Q2 2025 Earnings Call Transcript

Celcuity Inc. (NASDAQ:CELC ) Q2 2025 Earnings Conference Call August 14, 2025 4:30 PM ET Company Participants Brian F. Sullivan - Co-Founder, Chairman & CEO Vicky Hahne - Chief Financial Officer Confe...

2 weeks ago · seekingalpha.com

Celcuity: Positive Phase 3 Wild-Type ABC Data With Gedatolisib Leads To End Of 2025 Catalyst

Celcuity's phase 3 VIKTORIA-1 trial showed gedatolisib significantly improved progression-free survival in PIK3CA wild-type HR+/HER2- advanced breast cancer patients. NDA submission for gedatolisib in...

3 weeks ago · forbes.com

Celcuity: What's Happening With CELC Stock?

Celcuity stock (NASDAQ: CELC), a clinical-stage biotechnology company, experienced an extraordinary 3x surge in a single trading session, with shares rocketing from approximately $14 to a peak of $46 ...

3 weeks ago · invezz.com

Celcuity shares skyrocket as breast cancer drug combo shows dramatic Phase 3 success

Shares of Celcuity surged more than 186% on Monday after the biotechnology company reported highly positive topline results from a Phase 3 clinical trial of its investigational breast cancer treatment...

3 weeks ago · schaeffersresearch.com

Biotech Stock Blasting Off After Late-Stage Trial Results

Biotech stock Celcuity Inc (NASDAQ:CELC) is skyrocketing today, up 221% at $43.76 at last glance, after upbeat phase 3 trial results for its advanced breast cancer therapy, gedatolisib, which it hopes...

3 weeks ago · reuters.com

Celcuity's triple cancer drug combo tops AstraZeneca's in cutting progression in study

Celcuity said on Monday its experimental combination treatment delayed the progression of a type of advanced breast cancer, sending the biotech firm's shares surging more than twofold in premarket tra...